{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:01:50Z","timestamp":1780038110708,"version":"3.53.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Icaritin, a prenylated flavonoid extracted from\n                      <jats:italic>Epimedium<\/jats:italic>\n                      , induces apoptosis and modulates immunity with proven antitumor activity in hepatocellular carcinoma (HCC). This study aimed to compare survival outcomes of transarterial chemoembolization (TACE) plus Icaritin versus TACE alone in HCC patients with macrovascular invasion (MVI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective cohort study, conducted from October 2022 to June 2025, included 288 patients with HCC and MVI from five tertiary hospitals. Patients were assigned to either the TACE plus Icaritin group (n = 144) or the TACE monotherapy group (n = 144). Tumor response was evaluated by mRECIST on contrast-enhanced CT\/MRI. Overall survival and progression-free survival were estimated using Kaplan Meier curves and compared by log-rank test; prognostic factors were identified via Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Icaritin\u2013TACE group showed significantly better outcomes, with longer median OS (16.3 vs. 13.3 months; P\u00a0=\u00a00.020) and PFS (8.5 vs. 7.6 months; P\u00a0=\u00a00.006) than the TACE monotherapy group. The disease control rate (DCR) was also higher in the Icaritin\u2013TACE group (84.0% vs. 72.2%; P\u00a0=\u00a00.015). Multivariate Cox regression analysis identified ECOG performance status, alpha-fetoprotein (AFP) levels, number of lesions, and maximum lesion diameter as independent predictors of OS, while lesion count was independently associated with PFS. The overall incidence of any grade adverse events was similar between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Icaritin combined with TACE improves OS, PFS, and DCR compared to TACE alone in patients with MVI-associated HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1684486","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:03:47Z","timestamp":1780034627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Huilin","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Interventional Therapy, Xinxiang Central Hospital \/ the Fourth Clinical College of Xinxiang Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Provincial Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Provincial Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bufu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhongshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Intervention, Ganzhou People's Hospital","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangping","family":"Cun","sequence":"additional","affiliation":[{"name":"Department of Radiology, the Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwen","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Provincial Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The First Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuancheng","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology Affiliated Hospital","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Provincial Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA-Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.016","article-title":"The chances of hepatic resection curing hepatocellular carcinoma","volume":"72","author":"Cucchetti","year":"2020","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004350","article-title":"Liver resection versus local ablation therapies for hepatocellular carcinoma within the milan criteria a systematic review and meta-analysis","volume":"273","author":"Shin","year":"2021","journal-title":"Ann Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13130150","article-title":"Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: Results of propensity score analyses","volume":"269","author":"Choi","year":"2013","journal-title":"Radiology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-22-469","article-title":"A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: Updates and insights","volume":"12","author":"Xie","year":"2023","journal-title":"Hepatobil Surg Nutr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt072","article-title":"Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: A large-scale multicenter study of 222 patients","volume":"24","author":"Zhao","year":"2013","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000545545","article-title":"Comparison of efficacy between lenvatinib and bevacizumab in combination of immune checkpoint inhibitor and interventional triple therapy in Chinese advanced hepatocellular carcinoma: The CLEAP 2302 study","volume":"14","author":"Pan","year":"2025","journal-title":"Liver Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108634","article-title":"Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis","volume":"257","author":"Wang","year":"2024","journal-title":"Pharmacol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.12.064","article-title":"Iodine-131 radioembolization boosts the immune activation enhanced by icaritin\/resiquimod in hepatocellular carcinoma","volume":"378","author":"Li","year":"2025","journal-title":"J Control Release"},{"key":"B11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40779-022-00433-9","article-title":"Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma","volume":"9","author":"Lu","year":"2022","journal-title":"MILITARY Med Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.0c00708","article-title":"Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma","volume":"14","author":"Yu","year":"2020","journal-title":"ACS Nano"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14641","article-title":"Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival","volume":"111","author":"Qin","year":"2020","journal-title":"Cancer Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1200\/JCO.2021.39.15_suppl.4077","article-title":"A randomized, double-blinded, phase III study of icaritin versus huachashu as the first-line therapy in biomarker-enriched HBV-related advanced hepatocellular carcinoma with poor conditions: Interim analysis result","volume":"39","author":"Sun","year":"2021","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2022.12.001","article-title":"Multidisciplinary strategies to enhance therapeutic effects of flavonoids from epimedii folium: Integration of herbal medicine, enzyme engineering, and nanotechnology","volume":"13","author":"Lu","year":"2023","journal-title":"J Pharm Anal"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"key":"B17","unstructured":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: An update for the age of artificial intelligence\n          \n          \n            \n              Riaz\n              A\n            \n            \n              Agha\n            \n            \n              Mathew\n              G\n            \n            \n              Rashid\n              R\n            \n            \n              Kerwan\n              A\n            \n            \n              Al-Jabir\n              A\n            \n          \n          \n          2025"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1831","article-title":"Survival in patients with recurrent intermediate-stage hepatocellular carcinoma sorafenib plus TACE vs TACE alone randomized clinical trial","volume":"10","author":"Fan","year":"2024","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2025.04.042","article-title":"Immune-activated microspheres for enhanced chemoembolization of hepatocellular carcinoma by blocking the adenosine A2A receptor","volume":"199","author":"Chen","year":"2025","journal-title":"Acta Biomater"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.22175","article-title":"New insights into the anticancer therapeutic potential of icaritin and its synthetic derivatives","volume":"85","author":"Reyes-Hernandez","year":"2024","journal-title":"Drug Dev Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609295","article-title":"Icaritin induces anti-tumor immune responses in hepatocellular carcinoma by inhibiting splenic myeloid-derived suppressor cell generation","volume":"12","author":"Tao","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.12.001","article-title":"Pan-asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO","volume":"31","author":"Chen","year":"2020","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0402","article-title":"Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective","volume":"29","author":"Xie","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01881-2","article-title":"HBP1-mediated transcriptional repression of AFP inhibits hepatoma progression","volume":"40","author":"Cao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma a review","volume":"10","author":"Cappuyns","year":"2024","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1684486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:03:50Z","timestamp":1780034630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1684486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1684486"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1684486","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1684486"}}